A prospective, randomized, multicenter, comparative and open-label study on hepatotoxicity of anastrozole compared with tamoxifen in adjuvant therapy in postmenopausal women with hormone receptor plus early breast cancer

被引：0
|
作者：
Lin, Y. [1 ]
Liu, J. L. [2 ]
Zhang, X. H. [3 ]
Li, L. [4 ]
Hu, R. [5 ]
Liu, J. [6 ]
Deng, Y. C. [7 ]
Chen, D. D. [8 ]
Zhao, Y. B. [9 ]
Wang, S. M. [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China
[2] Guangxi Tumour Inst & Hosp, Nanning, Peoples R China
[3] Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Peoples R China
[4] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China
[5] Sichuan Canc Hosp, Chengdu, Peoples R China
[6] Fujian Prov Tumor Hosp, Fuzhou, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[8] Yunnan Tumor Hosp, Kunming, Peoples R China
[9] Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2067
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 50 条
  • [31] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Carlson, Robert W.
    O'Neill, Anne
    Vidaurre, Tatiana
    Gomez, Henry L.
    Badve, Sunil S.
    Sledge, George W.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1049 - 1056
  • [32] ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial-anastrozole is superior to tamoxifen as adjuvant treatment in postmenopausal women with early breast cancer.
    Bianco, R
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S155 - S155
  • [33] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
    Karnon, Jonathan
    Delea, Thomas
    Barghout, Vicki
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (02): : 171 - 183
  • [34] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
    Jonathan Karnon
    Thomas Delea
    Vicki Barghout
    [J]. The European Journal of Health Economics, 2008, 9
  • [35] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
    Binghe Xu
    Huiping Li
    Zefei Jiang
    Lin Gu
    Jinhai Tang
    Hui Xie
    Yueyin Pan
    Yunjiang Liu
    Shude Cui
    Xiaojia Wang
    Li Cai
    Yiqiong Zhang
    Huadong Zhao
    Zhimin Shao
    [J]. Chinese Journal of Cancer Research, 2022, 34 (06) : 592 - 601
  • [36] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
    Xu, Binghe
    Li, Huiping
    Jiang, Zefei
    Gu, Lin
    Tang, Jinhai
    Xie, Hui
    Pan, Yueyin
    Liu, Yunjiang
    Cui, Shude
    Wang, Xiaojia
    Cai, Li
    Zhang, Yiqiong
    Zhao, Huadong
    Shao, Zhimin
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (06) : 592 - +
  • [37] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer.
    Delea, T. E.
    Karnon, J.
    Sofrygin, O.
    Thomas, S. K.
    Barghout, V
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S116 - S117
  • [38] COST-EFFECTIVENESS ANALYSIS OF AROMATASE INHIBITORS AND TAMOXIFEN AS AN ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY-STAGE HORMONE RECEPTOR POSITIVE BREAST CANCER
    Sura, S. D.
    Sansgiry, S. S.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A220 - A220
  • [39] Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer
    van de Velde, C.
    Seynaeve, C.
    Hasenburg, A.
    Rea, D.
    Vannetzel, J. M.
    Paridaens, R.
    Markopoulos, C.
    Smeets, J.
    Nortier, J. W. R.
    Jones, S. E.
    [J]. EJC SUPPLEMENTS, 2009, 7 (03): : 1 - 1
  • [40] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
    Johnston, Stephen R. D.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
12345